公开(公告)号：US20190322685A1

公开(公告)日：2019-10-24

申请号：US16469174

申请日：2017-12-14

Applicant: Janssen Pharmaceutica NV

Inventor： Patrick René ANGIBAUD ,  Vineet PANDE ,  Barbara HERKERT ,  Daniel Jason KROSKY ,  Olivier Alexis Georges QUEROLLE ,  Aaron Nathaniel PATRICK ,  Isabelle Noëlle Constance PILATTE

IPC: C07D495/04 ,  A61P35/02

Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to azepane compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

公开(公告)号：US20200172556A1

公开(公告)日：2020-06-04

申请号：US16789707

申请日：2020-02-13

Applicant: Janssen Pharmaceutica NV

Inventor： Patrick Rene ANGIBAUD ,  Vineet PANDE ,  Barbara HERKERT ,  Daniel Jason KROSKY ,  Olivier Alexis Georges QUEROLLE ,  Aaron Nathaniel PATRICK

IPC: C07D519/00 ,  A61P35/02 ,  A61P3/10

Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

公开(公告)号：US20190218230A1

公开(公告)日：2019-07-18

申请号：US16331579

申请日：2017-09-13

Applicant: Janssen Pharmaceutica NV

Inventor： Patrick Rene ANGIBAUD ,  Vineet PANDE ,  Barbara HERKERT ,  Daniel Jason KROSKY ,  Olivier Alexis Georges QUEROLLE ,  Aaron Nathaniel PATRICK

IPC: C07D519/00 ,  A61P3/10 ,  A61P35/02

CPC classification number: C07D519/00 ,  A61P3/10 ,  A61P35/02 ,  C07D519/04

Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

公开(公告)号：US20230039917A1

公开(公告)日：2023-02-09

申请号：US17734413

申请日：2022-05-02

Applicant: Janssen Pharmaceutica NV

Inventor： Xuedong DAI ,  Olivier Alexis Georges QUEROLLE ,  Daniel Jason KROSKY ,  Wei CAI ,  Liqiang FU ,  Linglong KONG ,  Yingtao LIU ,  Zhao-Kui WAN ,  Barbara MORSCHHÄUSER GEB. HERKERT ,  Vineet PANDE ,  James Patrick EDWARDS ,  Aaron Nathaniel PATRICK ,  Patrick René ANGIBAUD ,  Virginie Sophie PONCELET

IPC: C07D495/04 ,  A61P35/00 ,  C07D519/00

Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

公开(公告)号：US20190211036A1

公开(公告)日：2019-07-11

申请号：US16331606

申请日：2017-09-13

Applicant: Janssen Pharmaceutica NV

Inventor： Patrick Rene ANGIBAUD ,  Vineet PANDE ,  Barbara HERKERT ,  Daniel Jason KROSKY ,  Olivier Alexis Georges QUEROLLE ,  Aaron Nathaniel PATRICK ,  Isabelle Noelle Constance PILATTE

IPC: C07D519/00 ,  A61P35/02 ,  A61P35/00

CPC classification number: C07D519/00 ,  A61P35/00 ,  A61P35/02

Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to spiro bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.